奎扎替尼

奎扎替尼
	IUPAC名; N-(5-tert-Butyl-1,2-oxazol-3-yl)-N′-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea
別名	AC220; AC010220; Vanflyta;
識別
CAS號	950769-58-1 [PubChem]
PubChem	24889392
ChemSpider	24640357
SMILES	CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6;
InChI	1/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36);
InChIKey	CVWXJKQAOSCOAB-UHFFFAOYAF
ChEBI	90217
DrugBank	DB12874
KEGG	D09955
IUPHAR配體	5658
性質
化學式	C29H32N6O4S
摩爾質量	560.67 g·mol−1
藥理學
ATC代碼	L01EX11（L01）
藥品分級
	若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。

奎扎替尼（Quizartinib）是一種用於治療急性骨髓性白血病的藥物，商品名為Vanflyta。^[2]

它是一種小分子受體酪氨酸激酶抑制劑。其分子靶點是FLT3，也稱CD135（一種原癌基因）。^[3]

它在2019年10月在日本獲許使用，^[4]2023年7月在美國得到批准。^[2]

參考文獻

^ Vanflyta- quizartinib tablet, film coated. DailyMed. 26 July 2023 [6 August 2023]. （原始內容存檔於7 August 2023）.
^ ^2.0 ^2.1 ^2.2 FDA approves quizartinib for newly diagnosed acute myeloid leukemia. U.S. Food and Drug Administration (FDA). 20 July 2023 [21 July 2023]. （原始內容存檔於21 July 2023）. 本文含有此來源中屬於公有領域的內容。
^ Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Journal of Medicinal Chemistry. December 2009, 52 (23): 7808–7816. PMID 19754199. doi:10.1021/jm9007533.
^ Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML (新聞稿). [16 February 2021]. （原始內容存檔於2023-08-10）.

Clinical trial number NCT02668653 for "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)" at ClinicalTrials.gov